The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: a real-world data cohort study
Visualitza/Obre
10.1016/j.aprim.2020.05.016
Inclou dades d'ús des de 2022
Cita com:
hdl:2117/330462
Tipus de documentArticle
Data publicació2020-10
EditorElsevier
Condicions d'accésAccés obert
Tots els drets reservats. Aquesta obra està protegida pels drets de propietat intel·lectual i
industrial corresponents. Sense perjudici de les exempcions legals existents, queda prohibida la seva
reproducció, distribució, comunicació pública o transformació sense l'autorització del titular dels drets
Abstract
Objective: We aimed to describe sociodemographic, comorbidities, co-medication and risk of thromboembolic events and bleeding in patients with NVAF initiating oral anticoagulants (OAC) for stroke prevention, and to estimate adherence and persistence to OAC.
Setting: Primary Health Care (PHC) in the Catalan Health Institute (ICS), Catalunya, Spain.
Participants: All NVAF adult patients initiating OAC for stroke prevention in August 2013-December 2015.
Methods: Population-based cohort study. Persistence was measured in patients initiating OAC in August 2013-December 2014.
Data source: SIDIAP, which captures electronic health records from PHC in the (ICS), covering approximately 5.8 million people.
Results: 51,690 NVAF patients initiated OAC; 47,197 (91.3%) were naive to OAC and 32,404 (62.7%) initiated acenocoumarol. Mean age was 72.8 years (SD 12.3) and 49.4% were women. Platelet-aggregation inhibitors were taken by 9,105 (17.6%) of the patients. Persistence and adherence were estimated up to the end of follow-up. For 22,075 patients, persistence was higher among the non-naive patients [n=258 (61.7%)] than among the naive [n=11,502 (53.1%)]. Adherence was estimated for patients initiating DOAC and it was similar in naive and non-naive patients. Among the naive to DOAC treatment, those starting rivaroxaban showed a highest proportion [(n=360 (80.1%)] of good adherence at implementation (MPR>80%) while patients starting dabigatran were less adherent [n= 203 [47.8%)].
Conclusions: Acenocoumarol was the most frequently prescribed OAC as first therapy in NVAF patients. Non-naive to DOAC showed better persistence than naive. Rivaroxaban showed higher proportion of adherent patients during the implementation phase than apixaban and dabigatran the lowest.
Descripció
© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
CitacióGiner-Soriano, M. [et al.]. The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: a real-world data cohort study. "Atención primaria", Octubre 2020, vol. 52, núm. 8, p. 529-538.
ISSN0212-6567
Fitxers | Descripció | Mida | Format | Visualitza |
---|---|---|---|---|
2020_Giner_Anticoagulants.pdf | 218,8Kb | Visualitza/Obre |